ArticleStem cell investigation2017
Article in Stem cell investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.Breast cancer research and treatment · 2024Article
- CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.Research square · 2024Article
- KRAB-ZFPs and cancer stem cells identity.Genes & diseases · 2023Review
- Review
- Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient's Prognosis.BioMed research international · 2022Article
- CD133 is an independent predictive and prognostic marker in metastatic breast cancer.Cancer biomarkers : section A of Disease markers · 2022Article
- CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells.Molecular therapy oncolytics · 2021Article
- The Role of Breast Cancer Stem Cell-Related Biomarkers as Prognostic Factors.Diagnostics (Basel, Switzerland) · 2020Review
- Review
- Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.Frontiers in immunology · 2020Review
- CD133 in Breast Cancer Cells: More than a Stem Cell Marker.Journal of oncology · 2019Review
- CD133 as a regulator of cancer metastasis through the cancer stem cells.The international journal of biochemistry & cell biology · 2019Review
- Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance.Molecules (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most commonly malignant cancers in women. CD133 protein is a widely used marker for isolating cancer stem cell (CSC). Its expression is associated with the prognosis of many cancers. However, whether
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.